Cefpodoxime Proxetil + Clavulanate Potassium Tablets Manufacturer in India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP formulates Cefpodoxime Proxetil + Clavulanate Potassium Tablets for bacterial infections where resistance to standard antibiotics becomes a clinical concern. The formulation is frequently prescribed in sinus infections, recurrent throat infections, urinary tract infections, bronchial infections, and bacterial ENT disorders requiring broader antibacterial intervention.

Cefpodoxime Proxetil delivers third-generation cephalosporin antibacterial activity against susceptible pathogens, while Clavulanate Potassium protects the antibiotic by inhibiting beta-lactamase enzymes produced by resistant bacterial organisms. This combination is regularly selected in outpatient therapies involving recurrent or difficult bacterial infections.

As a leading Cefpodoxime Clavulanate Tablets Manufacturer in India, Genliva Wellness LLP supplies advanced oral antibacterial formulations for pharmaceutical distributors, contract manufacturing partners, and regulated export markets.

Cefpodoxime Proxetil + Clavulanate Potassium Tablets are developed for resistant bacterial infection management.

Third-generation cephalosporin and clavulanate combination
Frequently utilized in recurrent bacterial infections
Enhanced antibacterial coverage against resistant organisms
Optimized oral antibiotic formulation
Manufactured under WHO GMP quality standards
Intended for advanced outpatient antibacterial therapies

This formulation is prescribed in resistant and recurrent bacterial infection treatment.

Treatment of sinus and throat infections
Management of urinary tract bacterial conditions
Administered in respiratory tract infections
Utilized in recurrent ENT bacterial disorders
Targets beta-lactamase producing bacteria
Frequently selected in outpatient antibiotic therapies

Cefpodoxime Proxetil + Clavulanate Potassium Tablets deliver broader antibacterial protection for difficult infections.

Improves antibacterial response in resistant conditions
Valuable in recurrent respiratory infection treatment
Extended cephalosporin antibacterial coverage
Frequently preferred in ENT bacterial therapies
Combines antibacterial and resistance-blocking mechanisms
Maintains strong oral antibacterial effectiveness